Clinical Microbiology: Open Access

Department of Therapeutic Research and Medicines Evaluation, National Center of Global Health, Istituto Superiore di Sanita, Rome, Italy

Publications

• Review Article   
  Paradigms of a Prophylaxis and Early Treatment in New Variants of SARS-CoV-2
  Author(s): Liliana Elena Weimer*, Cattari Giovanna, Fanales-Belasio Emanuele, Cuccuru Elena and Vidili Gianpaolo
  
  Despite the challenges of outpatient administration and associated costs, monoclonal antibodies were a mainstay of the COVID-19 armamentarium from November 2020, when bamlanivimab first received US food and drug administration Emergency Use Authorization (EUA), through November 2022, when the bebtelovimab EUA was revoked. Ideal qualities of treatments include effectiveness in preventing hospitalization and death, safety and tolerability for patients, easy administration in the outpatient environment, and cost-effectiveness. Monoclonal Antibodies (mAbs) that neutralize SARS-CoV-2 fit the safety and efficacy profile in early randomized clinical trials. Monoclonal antibodies targeting the anti-SARS-CoV-2 Spike (S) protein are prescribed in high income countries to prevent severe disease in at risk patients. Although studies report efficacy as between 50% to 85%, globa.. View more»
  

  DOI: 10.35248/2327-5073.23.12.343

  Abstract HTML PDF